VEGFA and neoplasm: It was demonstrated that specific monoclonal antibodies could block VEGF-induced angiogenesis both in vivo and in vitro, providing the first evidence that the targeting of a paracrine mediator affecting the vasculature could significantly inhibit tumor growth.